Visual Clean Is Not Cleaning Validation

Visual Clean Is Not Cleaning Validation

Clean can be a dangerous word.

It sounds final.

It sounds reassuring.

It sounds like the problem is handled.

But in pharma, especially with shared equipment, "it looks clean" is not the same as "we have proven the equipment is clean enough for the next product."

That difference matters.

FDA's July 24 warning letter to Dabur India Limited is a current reminder of why.

FDA cited cleaning-validation concerns for non-dedicated equipment, including reliance on visual inspection, lack of scientifically determined maximum allowable carryover limits, lack of quantitative residue testing, and lack of direct surface sampling of difficult-to-clean areas.

That is the source fact.

The operator lesson is blunt:

Visual clean is not cleaning validation.

It is a starting observation.

Not the control strategy.

Shared Equipment Changes the Burden

Dedicated equipment is simpler.

Not easy.

Simpler.

Shared equipment raises the bar because the risk does not end when one batch ends.

Residue from Product A can become a problem for Product B.

A hard-to-clean gasket can become a recurring blind spot.

A transfer path can become the place everyone assumes was covered by the main cleaning step.

A visual check can miss what science was supposed to measure.

That is why shared-equipment cleaning validation has to answer practical questions:

What are we trying to remove?

How much is acceptable?

Where is residue most likely to remain?

How do we sample those locations?

What method can detect the residue at the level that matters?

What happens while remediation is underway?

And what product risk already exists from prior use?

If the system cannot answer those questions, the equipment may be shiny.

The control is not.

Visual Inspection Has a Place

Visual inspection is not useless.

It can catch gross failures.

It can support routine execution.

It can be part of a cleaning program.

But it cannot carry the whole burden for shared-equipment validation.

Eyes are not validated analytical methods.

No offense to eyes.

They do important work.

They also miss things.

Cleaning validation needs science behind it: residue limits, method suitability, recovery, swab locations, worst-case rationale, direct sampling where appropriate, and evidence that the cleaning process consistently performs.

That is what lets Quality make a defensible decision.

Not vibes.

Not shine.

Evidence.

The Usage Record Matters More Than People Think

FDA's letter also cited quality-unit and production-record integrity concerns, including FDA's statement that an equipment usage logbook provided during inspection was falsified and omitted multiple U.S. marketed OTC drug products that were documented in the original logbook.

That fact pattern matters for cleaning validation.

If the equipment-use history is unreliable, the cleaning story gets harder to defend.

What products actually ran?

What sequence did they run in?

What worst-case conditions applied?

Which batches may have been exposed to risk?

What cleaning procedure was used between runs?

What evidence supports the next product's release?

A cleaning validation program depends on knowing how equipment is actually used.

If the record is wrong, the risk assessment starts on unstable ground.

And unstable ground is a poor foundation for batch release.

Interim Controls Are Not Optional

One of the common remediation traps is acting like the future fix solves the current risk.

It does not.

A new procedure may be coming.

A new method may be in development.

A revalidation plan may be approved.

A consultant may have been summoned, which is how you know everyone is serious now.

Fine.

But what happens today?

FDA stated Dabur's response did not address interim controls to mitigate cross-contamination risk during remediation.

That is the key leadership question.

While the full remediation is being built, what controls protect product now?

Do you pause shared use?

Do you dedicate equipment?

Do you add enhanced cleaning verification?

Do you quarantine affected inventory?

Do you expand testing?

Do you perform a broader retrospective review?

Do you hold release until risk is understood?

The answer depends on the site and the product.

But there has to be an answer.

"We will fix it later" is not an interim control.

It is a hope with a timeline.

Retrospective Review Has to Be Real

When cleaning validation was weak, the question is not only how to fix the process going forward.

The question is what already happened.

Which products ran on the equipment?

Which residues matter?

Which batches are still within expiry?

Which markets received them?

What testing or scientific rationale can support continued distribution?

What complaints, deviations, or trends need to be reviewed?

What customer or recall actions could be needed if risk is confirmed?

This is where teams sometimes get timid.

They want the retrospective review to be small because the business risk is large.

Understandable.

Wrong direction.

The review has to be scoped to the quality risk, not the comfort level of the room.

The Operator Test

If you own manufacturing, Quality, Validation, Tech Ops, or remediation, walk the line and the records together.

Not separately.

Together.

Can the team show which products actually used the equipment?

Can they defend the worst-case cleaning rationale?

Can they show carryover limits that are scientifically justified?

Can they show quantitative residue testing where it is needed?

Can they identify and sample difficult-to-clean areas?

Can they explain interim controls during remediation?

Can they trace potential impact to products already distributed?

Can the quality unit trust the underlying records?

That last one is not a footnote.

It is central.

Cleaning validation is only as strong as the process knowledge and records underneath it.

Clean Enough Has to Mean Something

The goal is not to make cleaning validation more complicated for sport.

The goal is to make "clean enough" scientifically meaningful.

Shared equipment can be controlled.

But control has to be proven.

With real limits.

Real sampling.

Real methods.

Real equipment-use history.

Real interim decisions.

Real product-risk review.

That is how teams move from visible cleanliness to validated control.

And that is where the work has to live.

Not in the shine.

In the evidence.

Website Publishing Notes

• Stage as Squarespace draft only.
• Set author to Two Pharma Guys.
• Add source URL in the post settings.
• Use the hero image and alt text provided above.
• Do not publish until Micah approves.